China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Update

Posted by Brenda Bartman on Jul 17th, 2026

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Get Free Report) saw a significant decrease in short interest in June. As of June 30th, there was short interest totaling 45,019 shares, a decrease of 37.4% from the June 15th total of 71,896 shares. Based on an average daily volume of 50,754 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.1% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, July 10th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, China SXT Pharmaceuticals currently has a consensus rating of “Sell”.

Read Our Latest Report on SXTC

China SXT Pharmaceuticals Price Performance

China SXT Pharmaceuticals stock opened at $2.54 on Friday. China SXT Pharmaceuticals has a 12 month low of $1.25 and a 12 month high of $1,046.98. The business has a 50 day simple moving average of $2.02 and a 200-day simple moving average of $18.65. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.76 and a current ratio of 7.94.

China SXT Pharmaceuticals (NASDAQ:SXTC – Get Free Report) last posted its quarterly earnings data on Wednesday, July 1st. The company reported ($0.07) earnings per share (EPS) for the quarter. The business had revenue of $0.26 million for the quarter.

Institutional Trading of China SXT Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. XTX Topco Ltd acquired a new position in shares of China SXT Pharmaceuticals in the 4th quarter valued at $36,000. Virtu Financial LLC grew its position in China SXT Pharmaceuticals by 107.5% in the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after acquiring an additional 15,013 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of China SXT Pharmaceuticals in the third quarter valued at approximately $78,000. Hedge funds and other institutional investors own 5.02% of the company’s stock.

About China SXT Pharmaceuticals

(Get Free Report)

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.